First positive DSMB with QGC001 in hypertension
Quantum Genomics, a French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases, received the first positive recommendation from the Data Safety Monitoring Board (DSMB) to continue QGC001’s phase 2a trial in hypertension. QGC001 is a first-in-class drug candidate addressing resistant hypertension, a serious condition affecting 100 to 150 million people worldwide, for which there is currently no effective drug. According to the World Health Organization,out of the 17 million cardiovascular-related deaths worldwide, this disease accounted for almost 10 million deaths in 2013. This positive recommendation by DSMB allows the company to pursue the development of this drug while preparing the launch of a second clinical program in congestive heart failure in mid-2016. Moreover, Quantum Genomics’ partner in animal health could exercise an option to licence QGC101 for the treatment of heart failure in dogs by the end of the year, under terms that have yet to be negotiated.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.